Long-term clinical evaluation of an adsorbent column (BM-01) of direct hemoperfusion type for beta 2-microglobulin on the treatment of dialysis-related amyloidosis.
Long-term clinical evaluation of an adsorbent column (BM-01) of direct hemoperfusion type for beta 2-microglobulin on the treatment of dialysis-related amyloidosis.
复制标题
直接血液灌流型β2微球蛋白吸附柱（BM-01）治疗透析相关淀粉样变性的长期临床评价。
DOI：
10.1111/j.1525-1594.1995.tb02289.x
复制
发表时间：
1995
影响因子：
2.4
通讯作者：
S. Takata
中科院分区：
文献类型：
--
作者：
F. Gejyo;T. Teramura;I. Ei;M. Arakawa;R. Nakazawa;N. Azuma;M. Suzuki;S. Furuyoshi;T. Nankou;S. Takata
对7例血液透析患者应用BM-01 β 2-微球蛋白（β 2 M）吸附柱治疗透析相关性淀粉样变性6个月以上的临床疗效和安全性进行了观察。血清β 2 M的下降百分比超过60- 70%，几乎所有患者每次治疗结束时的水平均低于10 mg/L。β 2 M的去除量计算为超过200-300 mg/疗程。结果表明，BM-01对β 2 M的去除效果非常好，能够维持β 2 M的时间平均浓度（TAC）低于25 mg/L，并改善临床症状。未观察到临床严重副作用。我们建议，BM-01应接受进一步的评价，其在透析相关淀粉样变性的长期治疗中的有用性，尽管用柱治疗可能无法成功预防疾病的发作。
The clinical efficacy and safety of a beta 2-microglobulin (beta 2M) adsorbent column, BM-01, on the treatment of dialysis-related amyloidosis were investigated in 7 hemodialysis patients for more than 6 months. The percent reduction of serum beta 2M was more than 60-70%, and the level at the end of each session was less than 10 mg/L in almost all patients. The amount of beta 2M removed was calculated as more than 200-300 mg/session. The results demonstrated that BM-01 performed very well for removing beta 2M, was capable of maintaining less than 25 mg/L of time average concentration (TAC) for beta 2M, and improved the clinical symptoms. Clinically severe side effects were not observed. We recommend that BM-01 should undergo further evaluation for its usefulness in the long-term treatment of dialysis-related amyloidosis, though treatment with the column may not be successful in preventing the onset of the disease.
DOI：
10.1016/0006-291x(85)91948-5
发表时间：
1985-01-01
影响因子：
3.1
作者：
GEJYO, F;YAMADA, T;SCHMID, K
通讯作者：
SCHMID, K